Download PDF
Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(06): 561-568
DOI: 10.1055/s-0041-1740951
Original Article

Real-World Experience of Treating Pediatric Chronic Myeloid Leukemia: Retrospective Study from a Cancer Center in Southern India

Authors

  • Sivasree Kesana

    1   Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

  • Venkatraman Radhakrishnan 

    1   Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

  • Jayachandran Perumal Kalaiyarasi 

    1   Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

  • Nikita Mehra 

    1   Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

  • Gangothri Selvarajan

    1   Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

  • Parathan Karunakaran

    1   Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

  • Krishnarathinam Kannan

    1   Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

  • Manikandan Dhanushkodi

    1   Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

  • Shirley Sundersingh

    2   Oncopathology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

  • Samson Mani

    3   Molecular Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

  • Trivadi S. Ganesan 

    1   Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

  • Tenali Gnana Sagar

    1   Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India

Funding None.
Further Information
Also available at
  Permissions and Reprints

Abstract

Introduction Chronic myeloid leukemia (CML) is rare in children and constitutes 2% of all leukemia. We present our institute experience in treating pediatric CML for 20 years.

Objectives There is a paucity of data on pediatric CML from India, hence we would like to present treatment responses and survival rates in our pediatric population treated with tyrosine kinase inhibitors at our center.

Materials and Methods Patients aged less than 18 years, diagnosed with CML from 2000 to 2019, and treated with imatinib were analyzed retrospectively considering demographic features, treatment characteristics, and survival outcomes. Descriptive analysis was done for the baseline characteristics. Event-free survival (EFS) and overall survival (OS) were calculated using the Kaplan-Meier method and the factors were compared using the log-rank test.

Results During the study period, 95 patients were diagnosed with CML of which 54 (56.8%) were males. The most common stage at presentation was the chronic phase (CP) with 84 (88.4%) patients followed by accelerated phase (AP) and blast crisis (BC) with 6 (6.3%) and 5 (5.3%) patients respectively. The median duration of follow-up for all patients was 98 months. EFS and OS at 8 years for patients with CML-CP were 43.1% and 80.4% respectively. Complete hematological response, complete cytogenetic response, and major molecular response was documented in 91 (95.7%), 73 (76.8%), and 63 (66.3%) patients respectively.

Conclusion Outcomes in pediatric CML are comparable to that of adults. Imatinib is well tolerated in children.

Keywords

pediatric - chronic myeloid leukemia - imatinib - responses - survival outcomes

Availability of Data and Material

The data regarding the findings of this study are available on request from the corresponding author.


Author Contributions

All coauthors have reviewed and contributed substantively and intellectually to the work described.


Note

Abstract on “A Retrospective Study of Pediatric Chronic Myeloid Leukemia” from 2000 to 2016 was presented in HAEMATOCON and PHOCON conferences in 2018, ICKSH-2019.


Supplementary Material



Publication History

Article published online:
31 December 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India